Moleculin Biotech MBRX
NASDAQ MBRX
$0.50 +0.00 (+0.68%)
At close: Oct 1, 2026 · 4:00 PM EDT

Moleculin Biotech (MBRX) Long-Term Debt Issuances (2016)

Updated

Moleculin Biotech's Long-Term Debt Issuances came in at $165,000 for FY2016, down 63.3% from $450,000 in FY2015.

Analysis

Moleculin Biotech (MBRX) Long-Term Debt Issuances (2016) Analysis & Trends

  • Per Business Quant, earlier years put Long-Term Debt Issuances at $450,000 in FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 1.98 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Moleculin Biotech 2.84 Mn 2.84 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2016 165,000.00
API Access

Moleculin Biotech Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=MBRX&period=max&api_key=YOUR_API_KEY